Tom Heyman

Tom Heyman has a long-standing track record of leadership and management in the biopharmaceutical industry, with particular experience in business development and venture capital. Spanning his 37-year career with Johnson & Johnson, Tom held a diverse range of leadership roles across legal, R&D, business development, general corporate management and equity investments. Previously, he served as president of JJDC, the venture capital group within Johnson & Johnson, where he managed approximately $1.5 billion of capital and oversaw investments in over 120 companies. Prior to his time at JJDC, Mr. Heyman spent 23 years leading business development for Johnson & Johnson’s pharmaceutical group, Janssen. Tom currently serves on the Board of Directors of Adagio Therapeutics.

Tom graduated as Master of Law from the K.U. Leuven in Belgium. He continued with post-graduate studies in International Law in Geneva, Switzerland, and post-graduate studies in business management at the University of Antwerp in Belgium.